News
Direct immunofluorescence biopsy may be a useful tool in the diagnosis of pediatric patients with potential immune-mediated skin disorders.
Which treatments work best for bullous pemphigoid (a rare, itchy skin disease that causes blisters)? Key messages • A cream, containing topical steroid clobetasol propionate, applied on the entire ...
Bullous pemphigoid is the most frequent autoimmune bullous disease and mainly affects elderly individuals. Increase in incidence rates in the past decades has been attributed to population aging, drug ...
The many different types of BP can cause difficulty in diagnosis, especially in the variants that present similarly to other dermatological diseases. Generalized erythroderma BP (GEBP) presents ...
Treatment and Prognosis Patients with BP will often go into remission if young, usually less than 65 years old, and in good health, but erupting blisters can continue for 10 or more years. About ...
The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
The approval of Dupixent for bullous pemphigoid is expected to offer new hope to patients who have previously faced limited treatment options. With the potential to effectively manage symptoms and ...
Patients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg (53 individuals) or placebo (53 individuals) added to standard-of-care oral corticosteroids. At 36 ...
Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.
Bullous pemphigoid is an autoimmune subepidermal blistering dermatosis that is uncommon in childhood. We report a case of a female infant, 3 months old, which presented clinical and laboratory data ...
Hosted on MSN28d
FDA Approves Dupixent for Bullous Pemphigoid - MSNPatients with moderate-to-severe bullous pemphigoid were randomly assigned to receive Dupixent 300 mg (53 individuals) or placebo (53 individuals) added to standard-of-care oral corticosteroids.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results